
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
Key Takeaways
- Regulatory labeling in Europe permits use regardless of identified RAS mutation, while the US indication includes post–systemic therapy patients and those ineligible for multiagent regimens.
- RASolute 302 demonstrated OS 13.2 vs 6.7 months overall and 13.2 vs 6.6 months in RAS G12–mutated disease, with 12-month OS 53.2% vs 17.3%.
The European Commission (EC) has approved daraxonrasib (Rasonque) as monotherapy for the treatment of adult patients with metastatic pancreatic adenocarcinoma previously treated with at least 1 systemic therapy, regardless of whether a RAS mutation has been detected in the tumor.1
The approval was based on findings from the phase 3, randomized, open-label RASolute 302 trial (NCT06625320).1,2 Data from the trial's first interim analysis, presented at the
In the RAS G12–mutated population, in which OS and progression-free survival (PFS) served as the dual primary end points, median OS was 13.2 months with daraxonrasib (n = 228) vs 6.6 months with chemotherapy (n = 231; HR, 0.40; 95% CI, 0.30-0.54; P < .0001). Median PFS by blinded independent central review (BICR) in this group was 7.3 months vs 3.5 months, respectively (HR, 0.45; 95% CI, 0.34-0.59; P < .0001).
In the overall population, median PFS by BICR was 7.2 months with daraxonrasib vs 3.6 months with chemotherapy (HR, 0.49; 95% CI, 0.38-0.64; P < .0001). The confirmed objective response rate (ORR) by BICR was 31.6% vs 11.2% in the overall population and 33.2% vs 11.8% in the RAS G12–mutated population (P < .0001 for both).
"For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches,” Thomas Seufferlein, MD, PhD, medical director of the Clinic for Internal Medicine I at Ulm University Hospital, stated in a news release.1 “The EC approval of daraxonrasib represents an important advance for patients with this aggressive and difficult-to-treat disease. The unprecedented survival benefit demonstrated in the RASolute 302 clinical trial underscores the potential of daraxonrasib to establish a new standard of care for eligible patients with metastatic pancreatic cancer across the European Union.”
In the United States,
How was the RASolute 302 trial designed?
RASolute 302 included patients who had received 1 prior fluoropyrimidine- or gemcitabine-based regimen in the metastatic setting, had an ECOG performance status of 0 or 1, and had tumor RAS status documented by local testing, defined as a KRAS, NRAS, or HRAS mutation at codon 12, 13, or 61, or no RAS mutation identified.2
Key exclusion criteria were prior RAS-targeted therapy, current or past central nervous system metastases, any condition that could impair absorption of an oral drug, and major surgery in the 4 weeks before randomization.4
Patients were randomly assigned 1:1 to oral daraxonrasib at 300 mg once daily (n = 248) or investigator's choice of chemotherapy (n = 252), comprising gemcitabine plus nab-paclitaxel (Abraxane), modified FOLFIRINOX, liposomal irinotecan (Onivyde) plus fluorouracil and leucovorin, or FOLFOX.2 Randomization was stratified by ECOG performance status, metastatic disease at diagnosis, liver metastases at baseline, and tumor RAS mutational status.
The dual primary end points were OS and PFS by BICR per RECIST 1.1 criteria in the RAS G12–mutated population. Key secondary end points included OS and PFS in the overall population, ORR in both populations, and time to deterioration in PROs for pain and global health status/quality of life.
What safety findings were reported?
Median time on treatment was 6.2 months with daraxonrasib. Treatment-related adverse effects (TRAEs) of any grade occurred in 97.9% of patients treated with daraxonrasib (n = 241) vs 93.5% of those treated with chemotherapy (n = 214). Grade 3 or higher TRAEs occurred in 43.6% vs 57.5% of patients, and serious TRAEs occurred in 10.8% vs 18.7%, respectively. TRAEs led to dose reductions in 36.1% vs 57.5% of patients, respectively, and to discontinuation at respective rates of 1.2% and 11.2%. One patient in the daraxonrasib arm died of treatment-related pneumonitis.
The most common TRAEs with daraxonrasib were rash (any grade, 85%; grade 3 or higher, 14%), diarrhea (58%; 5%), stomatitis (53%; 12%), nausea (46%; 2%), and vomiting (37%; <1%). Rash (17.4%) and stomatitis (6.6%) were the most frequent TRAEs leading to dose reduction with daraxonrasib.
References
- European Commission approves Revolution Medicines' Rasonque (daraxonrasib), the first broad RAS-targeted medicine in metastatic pancreatic cancer. News release. Revolution Medicines. November 16, 2026. Accessed November 16, 2026. https://www.revmed.com/media/news/13736/european-commission-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer
- Wolpin BM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): primary and final analysis from the phase 3 RASolute 302 study. Paper presented at: 2026 ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL
- FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. FDA. August 26, 2026. Accessed November 16, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma
- Phase 3 study of daraxonrasib (RMC-6236) in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) (RASolute 302). ClinicalTrials.gov. Updated June 2, 2026. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT06625320
Related to this article








